U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24O2
Molecular Weight 296.4041
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHINYL ESTRADIOL

SMILES

C#C[C@@]1(CC[C@@]2([H])[C@]3([H])CCc4cc(ccc4[C@@]3([H])CC[C@@]21C)O)O

InChI

InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

HIDE SMILES / InChI
Molecular Formula C20H24O2
Molecular Weight 296.4041
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html

Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). Used for treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Originator

Schering
46
Curator's Comment:: Introduced as Estinyl by Schering, US, in 1944

Approval Year

1943
59
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2456
Pregnancy
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Estrogen receptor alpha
Approved
7997
LESSINA-21

Approved Use

Indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

1016496000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
122.8 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1335.8 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Vomiting...
Other AEs:
Vomiting (23%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Mastalgia...
Other AEs:
Mastalgia (32%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Nausea...
Other AEs:
Nausea (48%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Disc. AE: Dysfunctional uterine bleeding, Uterine bleeding...
AEs leading to
discontinuation/dose reduction:
Dysfunctional uterine bleeding
Uterine bleeding
Headache
Mood change
Nausea
Acne
Weight gain
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
healthy, 29
Health Status: healthy
Age Group: 29
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
Disc. AE: Pulmonary embolism...
AEs leading to
discontinuation/dose reduction:
Pulmonary embolism
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Disc. AE: Thromboembolic event, Hepatic disease...
AEs leading to
discontinuation/dose reduction:
Thromboembolic event
Hepatic disease
Headache
Hypertension
Uterine bleeding
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Vomiting 23%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Mastalgia 32%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Nausea 48%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Acne Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Dysfunctional uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Mood change Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Nausea Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Weight gain Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Pulmonary embolism Disc. AE
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
healthy, 29
Health Status: healthy
Age Group: 29
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Hepatic disease Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Hypertension Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Thromboembolic event Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1470

inhibitor
1172
substrate
865

inhibitor
1318
inhibitor
1421

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
89

CYP3A5
66

CYP1B1
14

CYP1A2
1268

CYP2J2
16

CYP2C19
1215

CYP2C8
761

CYP2B6
679
P-gp
1223

UGT1A1
358

CYP1A1
302

CYP1A2
892

CYP2C19
830

CYP2C8
586

SULT1E1
8
CYP2A6
74

UGT
24
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1462
 yes [IC50 1.5 uM]
CYP1A2
1406
 yes [IC50 14 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4
CYP2J2
19
 yes [IC50 15 uM]
CYP2B6
845
 yes [IC50 19 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4
CYP1A1
188
 yes [IC50 2.1 uM]
CYP2C19
1277
 yes [IC50 2.8 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4
CYP2D6
1455
 yes [IC50 24 uM]
CYP3A5
119
 yes [IC50 3.3 uM]
CYP2C8
810
 yes [IC50 8.3 uM]
CYP1B1
64
 yes [IC50 9.2 uM]
CYP2C9
1362
 yes [IC50 9.2 uM]
CYP2A6
625
 yes
weak (co-administration study)
Comment: ~22% increase in clerance of nicotine
Page: 12
UGT
49
 yes
yes (co-administration study)
Comment: Coadministration with propranolol: ~70% increase in glucuronidation; Coadministration with lamotrigine: ~64% increase in glucuronidation
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
865
 major
CYP3A4
1470
 major
yes (co-administration study)
Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
CYP1A2
892
 minor
CYP2C19
830
 minor
CYP2C8
586
 minor
CYP1A1
302
 yes
P-gp
1223
 yes
SULT1E1
8
 yes
UGT1A1
358
 yes
yes (co-administration study)
Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00IKZ2
A2B Chem
AI66190
AK Scientific
H075
AK Scientific
J10401
APExBIO
A8428
AbovChem LLC
HY-B0216
Alfa Chemistry
ACM57636
Angene
AGN-PC-0SO487
AstaTech
H11762
BOC Sciences
57-63-6
Bide Pharmatech
BD34146
BioSynth
Q-201076
Bosche Scientific
E2751
Cayman Chemical
10006486
Chem Scene
CS-2161
Chem4Pharma
C4PST603
ChemShuttle
151467
Compound Cloud
5991
Enamine
EN300-119516
Fluorochem
358085
Fluorochem
393316
Frontier Scientific Services
500058033
Hangzhou APIChem Technology
AC-2169
Hangzhou Yuhao Chemical Technology
RT19571
HongKong Chemhere
SCE26184
IBScreen
Bio-0610
KeyOrganics
KS-5257
Lab Network
LN00243285
Lab Network
LN01776715
MedChem Express
HY-B0216
MolPort
MolPort-000-725-407
MolPort
MolPort-001-794-636
Molnova
M15786
PI Chemicals
PI-12363
Pharmeks
PHAR036137
Sigma Aldrich
02463|SIAL
Sigma Aldrich
1260001
Sigma Aldrich
1260001|USP
Sigma Aldrich
2463
Sigma Aldrich
46263
Sigma Aldrich
46263|SIAL
Sigma Aldrich
E1900000
Sigma Aldrich
E1900000|SIAL
Sigma Aldrich
E4876
Sigma Aldrich
E4876|SIGMA
Sigma Aldrich
PHR1480
Sigma Aldrich
PHR1480|SIAL
Sigma Aldrich
Y0001124
Sigma Aldrich
Y0001124|SIAL
TargetMol
57-63-6
TargetMol
HMDB0001926
TargetMol
T1424
Tetrahedron
TS35904
TimTec
SBB066068
TimTec
ST081364
W&J PharmaChem
50A425563
ZINC
ZINC000003812897
http://zinc15.docking.org/substances/ZINC000003812897
eMolecules
260186965
eMolecules
50286439
eMolecules
93466183
mcule
MCULE-5991854877
mcule
MCULE-8831464971
PubMed

PubMed

TitleDatePubMed
A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
2000 Dec
Method for non-invasively recording electrocardiograms in conscious mice.
2001
Biphasic versus monophasic oral contraceptives for contraception.
2001
Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans.
2001 Apr
High metabolization of catecholestrogens by type 1 estrogen sulfotransferase (hEST1).
2001 Apr
Oestrogens and oestrogenic activity in raw and treated water in Severn Trent Water.
2001 Apr
Effect of epomediol on ethinyloestradiol-induced changes in bile acid and cholesterol metabolism in rats.
2001 Aug
Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells.
2001 Aug
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.
2001 Feb
Metabolism of chylomicron cholesterol is delayed by estrogen. An in vivo study in the rat.
2001 Feb
Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
2001 Feb
[Comparison of 2 therapeutic strategies for severe endometriosis, in young women counsulting for sterility or pain. Results in cases of chronic pelvic pain].
2001 Feb
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
2001 Feb
Collaborative study on rat sperm motion analysis using CellSoft Series 4000 semen analyzer.
2001 Feb
Influence of low-dose oral contraceptives, alcohol, and grapefruit on.
2001 Jan
Lack of effect of alcohol on ethinylestradiol in premenopausal women.
2001 Jan
The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
2001 Jan
Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats.
2001 Jan-Feb
Development and validation of a homologous zebrafish (Danio rerio Hamilton-Buchanan) vitellogenin enzyme-linked immunosorbent assay (ELISA) and its application for studies on estrogenic chemicals.
2001 Jul
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
2001 Jul
Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium.
2001 Jul
Enhancement of splenic-macrophage Fcgamma receptor expression by treatment with estrogens.
2001 Jul
Ovarian and endometrial function during hormonal contraception.
2001 Jul
Survival and precopulatory behaviour of Gammarus pulex (L.) exposed to two xenoestrogens.
2001 Jul
Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells.
2001 Jul 30
A scheme of combined oral contraceptives for women more than 40 years old.
2001 Jul-Aug
Pubertal disorders in inv dup(15) syndrome.
2001 Jun
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.
2001 Jun
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
2001 Jun
Effects of the synthetic estrogen 17 alpha-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas).
2001 Jun
Determination of estrogens in river water by gas chromatography-negative-ion chemical-ionization mass spectrometry.
2001 Jun 15
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature.
2001 Mar
Applicability of micellar electrokinetic chromatography to the analysis of estrogens in water.
2001 Mar
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
2001 Mar
Practices of prescribing oral contraceptives in Poland.
2001 Mar
[Comparison of 2 therapeutic strategies in severe endometriosis, in young women consulting for sterility or pain. II. In the case of infertility, value of ovarian stimulation with intrauterine insemination after surgery].
2001 Mar
Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse.
2001 Mar
Effects of estrogens in vitro and in vivo on cartilage growth in the tilapia (Oreochromis mossambicus).
2001 Mar
Induction of gene expression in sheepshead minnows (Cyprinodon variegatus) treated with 17beta-estradiol, diethylstilbestrol, or ethinylestradiol: the use of mRNA fingerprints as an indicator of gene regulation.
2001 Mar
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection.
2001 Mar 16
Exposure of Chironomus riparius larvae to 17alpha-ethynylestradiol: effects on survival and mouthpart deformities.
2001 Mar 26
Breast cancer and HRT--what are the data?
2001 Mar-Apr
Diane 35 and spironolactone combination in the treatment of hirsutism.
2001 May
Testosterone 5alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma.
2001 May
Streamlined beta-galactosidase assay for analysis of recombinant yeast response to estrogens.
2001 May
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
2001 May
Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol.
2001 May
Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man.
2001 May-Jun
Effects of binary mixtures of six xenobiotics on hormone concentrations and morphometric endpoints of northern bobwhite quail (Colinus virginianus).
2001 May-Jun
Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits.
2001 Summer
Patents

Patents

20010002262
19
20010018073
2
JP2001328998A
1
JP2002145759A
5
JP2002543154A
5
JP2002543158A
5
JP2004520375A
3
JP2007197459A
1
JP2007512291A
11
JP2009102424A
1
JP3534775B2
2
JPH0873328A
1
JPS61251606A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Endometriosis
Route of Administration: Oral
In Vitro Use Guide
EE (
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:52:39 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:39 UTC 2021
Record UNII
423D2T571U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHINYL ESTRADIOL
EMA EPAR   HSDB   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
ORSYTHIA COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ORTHO-CEPT
Common Name English
OVRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF PREVIFEM
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SEASONIQUE
Common Name English
ETHINYL ESTRADIOL [VANDF]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ALESSE
Common Name English
FEMCON FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ESTROSTEP FE
Common Name English
MINASTRIN 24 FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF TRI LO SPRINTEC
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SEASONALE
Common Name English
MARLISSA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ISIBLOOM COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF DESOGEN
Common Name English
KELNOR COMPONENT ETHINYL ESTRADIOL
Common Name English
ZOVIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
AVIANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
QUARTETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL [HSDB]
Common Name English
ETHINYL ESTRADIOL [USP-RS]
Common Name English
NSC-10973
Code English
ETHINYL ESTRADIOL COMPONENT OF INTROVALE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF KELNOR
Common Name English
ELIFEMME COMPONENT ETHINYL ESTRADIOL
Brand Name English
LYNORAL
Brand Name English
KURVELO COMPONENT ETHINYL ESTRADIOL
Common Name English
SEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO TRI-CYCLEN COMPONENT ETHINYL ESTRADIOL
Common Name English
NORQUEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF VELIVET
Common Name English
PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF MIRCETTE
Common Name English
YAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ORTHO TRI-CYCLEN
Common Name English
ETHINYL ESTRADIOL [MI]
Common Name English
LYBREL COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TWIRLA
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF LEVONEST
Common Name English
BEYAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI-SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [EMA EPAR]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF YAZ
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ALTAVERA
Common Name English
SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOLUM [WHO-IP LATIN]
Common Name English
CYCLESSA COMPONENT ETHINYL ESTRADIOL
Common Name English
ESTROSTEP FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL
EP   INCI   INN   MART.   WHO-DD   WHO-IP  
INCI   INN  
Official Name English
ETHINYLESTRADIOL [INCI]
Common Name English
PORTIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYLESTRADIOL [EP MONOGRAPH]
Common Name English
LEVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF BEYAZ
Common Name English
ENSKYCE COMPONENT ETHINYL ESTRADIOL
Brand Name English
TWIRLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
17-ETHINYLESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-SPRINTEC
Common Name English
ARANELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SAFYRAL
Common Name English
ETHINYLESTRADIOL [MART.]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF YASMIN
Common Name English
NORDETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
XULANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ESTINYL
Brand Name English
ETHINYLESTRADIOL [WHO-DD]
Common Name English
QUASENSE COMPONENT ETHINYL ESTRADIOL
Common Name English
TAYTULLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYLESTRADIOL [INN]
Common Name English
ETHINYLOESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-PREVIFEM
Common Name English
ETHINYL ESTRADIOL COMPONENT OF OVRAL
Common Name English
PIMTREA COMPONENT ETHINYL ESTRADIOL
Brand Name English
SAFYRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
INTROVALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF LOSEASONIQUE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF QUASENSE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF CRYSELLE
Common Name English
KARIVA COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO-CEPT COMPONENT ETHINYL ESTRADIOL
Common Name English
LO MINASTRIN FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
FEMINONE
Brand Name English
TRI-PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
YASMIN COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LEVLITE
Common Name English
NUVARING COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI LO SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ANNOVERA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF KARIVA
Common Name English
ALTAVERA COMPONENT ETHINYL ESTRADIOL
Common Name English
MIRCETTE COMPONENT ETHINYL ESTRADIOL
Common Name English
VYFEMLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF ARANELLE
Common Name English
LO LOESTRIN FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [ORANGE BOOK]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF PREVEN
Common Name English
ENPRESSE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ALESSE COMPONENT ETHINYL ESTRADIOL
Common Name English
CRYSELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL [WHO-IP]
Common Name English
LEVLITE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LO LOESTRIN FE
Common Name English
SETLAKIN COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF NUVARING
Common Name English
VOLNEA COMPONENT ETHINYL ESTRADIOL
Brand Name English
DESOGEN COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SETLAKIN
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF SPRINTEC
Common Name English
VELIVET COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-LEGEST FE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF CYCLESSA
Common Name English
17ALPHA-ETHINYLESTRADIOL
Common Name English
PREVEN COMPONENT ETHINYL ESTRADIOL
Common Name English
LOSEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
VIENVA COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-NOR-17.ALPHA.-PREGNA-1,3,5(10)-TRIEN-20-YNE-3,17-DIOL
Common Name English
TRI-LEGEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
FEMHRT COMPONENT ETHINYL ESTRADIOL
Common Name English
LESSINA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF ANNOVERA
Brand Name English
BEKYREE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF FEMHRT
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LYBREL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF FEMCON FE
Common Name English
SEASONALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIPHASIL COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF NORQUEST FE
Common Name English
VIORELE COMPONENT ETHINYL ESTRADIOL
Brand Name English
NORINYL COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-NORPREGNA-1,3,5(10)-TRIEN-20-YNE-3,17-DIOL, (17.ALPHA.)-
Common Name English
BREVICON COMPONENT ETHINYL ESTRADIOL
Brand Name English
LEVONEST COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QG03AA06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NDF-RT N0000000100
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/LEV)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA13
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA10
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03CA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QL02AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NDF-RT N0000175825
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA15
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/NOR)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NCI_THESAURUS C478
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA12
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA16
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA12
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA08
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03CA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA09
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA10
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
FDA ORPHAN DRUG 28788
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA08
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
LIVERTOX 382
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA11
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA13
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA16
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA15
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA09
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
EMA ASSESSMENT REPORTS EVRA (AUTHORIZED: CONTRACEPTION)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA11
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC L02AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
Code System Code Type Description
EVMPD
SUB07277MIG
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
FDA UNII
423D2T571U
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
PUBCHEM
5991
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
NCI_THESAURUS
C486
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ETHINYL ESTRADIOL
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY Description: A white to slightly yellowish white, crystalline powder; odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in acetone R and dioxan R.Category: Estrogen.Storage: Ethinylestradiol should be kept in a well-closed container, protected from light.Additional information: Ethinylestradiol may exist in 2 polymorphic forms one of which melts at about 183?C, the other, metastable, at about 143?C.RequirementsDefinition: Ethinylestradiol contains not less than 97.0% and not more than 102.0% of C20H24O2, calculated with reference to the dried substance.
ChEMBL
CHEMBL691
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
DRUG BANK
DB00977
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
MERCK INDEX
M5058
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY Merck Index
MESH
D004997
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
LACTMED
Ethinyl Estradiol
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
EPA CompTox
57-63-6
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-342-2
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
RXCUI
4124
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1260001
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY USP-RS
INN
437
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
IUPHAR
7071
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
DRUG CENTRAL
1082
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
CAS
57-63-6
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
HSDB
3587
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
WIKIPEDIA
ETHINYL ESTRADIOL
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
Related Record Type Details
Structure of ETHINYL ESTRADIOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
Structure of ETHYNYL ESTRADIOL 17-SULFATE
DERIVATIVE -> PARENT
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of ETHINYL ESTRADIOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of ETHYNYLESTRADIOL-3-O-GLUCURONIDE
METABOLITE -> PARENT
MAJOR
URINE
Structure of 10.BETA.-HYDROXY-19-NORETHISTERONE
METABOLITE -> PARENT
Structure of 2-HYDROXYETHINYLESTRADIOL
METABOLITE -> PARENT
Structure of ETHYNYLESTRADIOL 3-SULFATE
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of MESTRANOL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of 9,11-DEHYDRO ETHYNYL ESTRADIOL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.BETA.-HYDROXY-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALFATRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-OXO-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6,7-DEHYDROETHYNYLESTRADIOL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 17.BETA.-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.ALPHA.-HYDROXY-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 16-OXO-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ESTRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of ETHINYL ESTRADIOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966